2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Carcinoma, Non-Small-Cell Lung
6
Neoplasm, Residual
3
Neoplasm Metastasis
3
Leukemia, Myeloid, Acute
3
Neoplasms
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Lung Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Colorectal Neoplasms
2
Uterine Cervical Neoplasms
1
Smoldering Multiple Myeloma
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Plasma Cell
1
Nasopharyngeal Carcinoma
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Large-Cell, Anaplastic
1
Leukemia, Promyelocytic, Acute
1
Leukemia, Plasma Cell
1
Interventions
Lenalidomide
17
Dexamethasone
15
Calcium Dobesilate
8
daratumumab
5
dexamethasone acetate
4
dexamethasone 21-phosphate
4
carfilzomib
4
auricularum
4
Melphalan
4
Leflunomide
3
Curcumin
3
isatuximab
2
iberdomide
2
elotuzumab
2
Peripheral Blood Stem Cell Transplantation
2
PVX-410 vaccine
2
Denosumab
2
Cyclophosphamide
2
Bortezomib
2
siltuximab
1
selinexor
1
sargramostim
1
pomalidomide
1
poly ICLC
1
piperine
1
pembrolizumab
1
ixazomib
1
ibrutinib
1
fludarabine phosphate
1
fludarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Smoldering Multiple Myeloma
×
Maintenance
×
Clear all
NCT00480363
2013-07-31
QUIREDEX
PETHEMA Foundation
Phase 3
Completed
120 enrolled